Pinetree Therapeutics Closes $17 Million in Series A Funding to Advance AbReptor™ Protein Degradation Platform and Portfolio Programs


July 30, 2024

Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca

July 23, 2024

PineTree Therapeutics Receives a Bits and Bytes Grant from Massachusetts Life Sciences Center

September 27, 2022

PineTree Therapeutics, Inc. Secures $23.5 Million of Series A1 Funding to Develop Cutting Edge Platform Technology to Create Therapeutic Assets for Unmet Medical Needs​
​
June 7, 2022
Pinetree Therapeutics
West Cambridge Scientific Park
767C Concord Ave
Cambridge MA 02138

​Website designed by Creative Eye Design